Related references
Note: Only part of the references are listed.A Rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding
Monica R. McClain et al.
GENETICS IN MEDICINE (2008)
Genetic determinants of response to warfarin during initial anticoagulation
Ute I. Schwarz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
HLA-B*5701 screening for hypersensitivity to abacavir
Simon Mallal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
A prototypical process for creating evidentiary standards for biomarkers and diagnostics
C. A. Altar et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Preclinical predictors of clinical safety: Opportunities for improvement
F. D. Sistare et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Promises of biomarkers in drug development a reality check
Estelle Marrer et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2007)
Personalized medicine: Elusive dream or imminent reality?
L. J. Lesko
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
The prospects for personalized medicine in drug development and drug therapy
J. Woodcock
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
The experience with voluntary genomic data submissions at the FDA and a vision for the future of the Voluntary Data Submission Program
M. S. Orr et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Paving the critical path: How can clinical pharmacology help achieve the vision?
L. J. Lesko
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Biornarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs
J. A. Wagner et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Biomarker qualification pilot process at the US food and drug administration
Federico Goodsaid et al.
AAPS JOURNAL (2007)
Opinion - A cost-effectiveness approach to the qualification and acceptance of biomarkers
Stephen A. Williams et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV Cohort study
A. Rauch et al.
CLINICAL INFECTIOUS DISEASES (2006)
Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions
Shuen-Lu Hung et al.
PHARMACOGENETICS AND GENOMICS (2006)
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity
P Dorr et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest™ in breast carcinoma
R Ainsworth et al.
JOURNAL OF CLINICAL PATHOLOGY (2005)